Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this research is to see if rosiglitazone also increases blood vessel growth in human fat cells. The investigators will compare results from before and after being on rosiglitazone for 6 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rosiglitazone to Reverse Metabolic Defects in Diabetes

NCT00094796

Diabetes Mellitus, Type II Insulin Resistance

COMPLETED PHASE2

Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone

NCT00746174

Insulin Sensitivity

COMPLETED PHASE4

Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease

NCT01574820

Prediabetes Coronary Artery Disease Insulin Resistance +1 more

COMPLETED PHASE3

Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.

NCT00154011

Healthy Subjects

COMPLETED NA

Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate

NCT00551564

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adipocytes play a crucial role in the control of metabolic homeostasis, by sequestering excess calories in the form of triglycerides, and secreting cytokines that control systemic fuel utilization. Sustained excess calorie consumption results in adipocyte hypertrophy and hyperplasia, and like any expanding tissue, requires increased capillary expansion to nourish the enlarged adipose tissue mass. Recent reports indicate that decreased capillary density in adipose tissue of obese individuals correlates with insulin resistance, suggesting that an imbalance of angiogenesis and adipogenesis may underlie this condition. To determine whether improvement in insulin sensitivity is related to changes in adipose tissue capillary development, we conducted a randomized, double-blind, placebo-controlled trial to determine capillary density, angiogenic growth potential, and metabolic parameters in healthy human volunteers before and after treatment with rosiglitazone, a potent insulin sensitizer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rosiglitazone

One 8mg capsule daily for 6 weeks.

Group Type EXPERIMENTAL

Rosiglitazone

Intervention Type DRUG

One 8mg capsule daily for 6 weeks.

Placebo

One capsule daily for 6 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

One capsule daily for 6 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosiglitazone

One 8mg capsule daily for 6 weeks.

Intervention Type DRUG

Placebo

One capsule daily for 6 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Avandia

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Overweight but otherwise in good general health.
2. Age 18 - 55 years.
3. Normal glucose tolerance.
4. Stable weight with BMI (27-44).
5. Stable medication use for the preceding month.
6. BP \< 150/90.
7. Negative pregnancy test (\*HCG), if female and of childbearing potential.
8. Practicing, and willing to continue to practice appropriate contraception throughout the study if a female of childbearing potential.

Exclusion Criteria

1. Serious medical illness.
2. Pregnancy.
3. Tobacco use within the past 6 months.
4. Prior or current treatment with a thiazolidinedione.
5. Patients who have received an investigational drug in the past 30 days.
6. Use of systemic corticosteroids.
7. Known or suspected allergy to Rosiglitazone or any component of the preparation

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes